AlphaCentric Advisors »

Candel Therapeutics shares owned by AlphaCentric Advisors

Quarter-by-quarter ownership of Candel Therapeutics (CADL) shares owned by AlphaCentric Advisors from 13F filings

Historical chart of AlphaCentric Advisors investment in Candel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Candel Therapeutics held by AlphaCentric Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Candel Therapeutics by AlphaCentric Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $178k 36k 4.90

More positions owned by AlphaCentric Advisors

Gilead Sciences (GILD)
Invesco Exchange Traded Fd T S&p500 Pur Val (RPV)
Ishares Tr Rus 1000 Val Etf (IWD)
Astrazeneca Ord (AZN)
Vertex Pharmaceuticals Incorporated (VRTX)
Euronet Worldwide (EEFT)
Invitation Homes (INVH)
Ionis Pharmaceuticals (IONS)
Insmed Com Par $.01 (INSM)
Incyte Corporation (INCY)
Roivant Sciences SHS (ROIV)
Argenx Se Sponsored Adr (ARGX)
Neurocrine Biosciences (NBIX)
AMREP Corporation (AXR)
Saul Centers (BFS)

View all positions for AlphaCentric Advisors

Top funds holding Candel Therapeutics

FMR
BlackRock
Portolan Capital Management
Acorn Capital Advisors
Vanguard Capital Management
Vanguard Group
Vestal Point Capital
Millennium Management
Geode Capital Management
Halter Ferguson Financial
State Street Corporation
Sands Capital Ventures
Northern Trust
Vanguard Fiduciary Trust
Vanguard Portfolio Management

View all funds holding Candel Therapeutics